Bill Cheliak
Plus aucun poste en cours
Fortune : 2 040 $ au 31/08/2023
Profil
William M.
Cheliak founded Fe Pharmaceuticals (Canada), Inc. in 2013, where he worked as Director & Vice President-Business Development.
Dr. Cheliak also formerly worked at Panag Pharma, Inc., as Chief Executive Officer from 2015 to 2019, MedBiome, Inc., as Chief Executive Officer from 2020 to 2021, Tetra Bio-Pharma, Inc., as Chairman from 2017 to 2021, Solarvest BioEnergy, Inc., as Independent Director, Xybion Digital, Inc., as Independent Director, Genizon Biosciences, Inc., as Vice President-Business Development, Supratek Pharma, Inc., as Vice President-Business Development and Alliances, and Neurodyn, Inc., as Vice President-Business Development.
Dr. Cheliak received his undergraduate degree and doctorate degree from the University of Alberta.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SOLARVEST BIOENERGY INC.
0,20% | 19/04/2023 | 120 000 ( 0,20% ) | 2 040 $ | 31/08/2023 |
Anciens postes connus de Bill Cheliak
| Sociétés | Poste | Fin |
|---|---|---|
| SOLARVEST BIOENERGY INC. | Président | 27/11/2023 |
| TETRA BIO-PHARMA INC. | Président | 28/05/2021 |
| MedBiome, Inc. | Directeur Général | 01/02/2021 |
Fe Pharmaceuticals (Canada), Inc.
 Fe Pharmaceuticals (Canada), Inc. Pharmaceuticals: MajorHealth Technology Fe Pharmaceuticals (Canada), Inc. operates as a research institution. It offers indication & treatment challenge, technical innovation and market services. The company was founded by William M. Cheliak and Bruce Holbein and is headquartered in Halifax, Canada. | Fondateur | 01/06/2020 |
Panag Pharma, Inc.
 Panag Pharma, Inc. Pharmaceuticals: MajorHealth Technology Panag Pharma, Inc. engages in the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Its product Topical A, provides a new approach to the treatment of chronic pain and inflammation. The company was founded by Mary Lynch, Melanie Kelly, Christian Lehmann, and Orlando Hung and is headquartered in Halifax, Canada. | Directeur Général | 01/05/2019 |
Formation de Bill Cheliak
| University of Alberta | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SOLARVEST BIOENERGY INC. | Utilities |
| TETRA BIO-PHARMA INC. | Health Technology |
| XYBION DIGITAL INC. | Finance |
| Entreprise privées | 6 |
|---|---|
Genizon Biosciences, Inc.
 Genizon Biosciences, Inc. BiotechnologyHealth Technology Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform. Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome). Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process. Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies. Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry. | Health Technology |
Supratek Pharma, Inc.
 Supratek Pharma, Inc. Pharmaceuticals: MajorHealth Technology Supratek Pharma, Inc. develops drugs and related oncology therapeutic products. It offers injectable chemotherapeutic that enhances or enables an approved anticancer drug. The firm’s products include SP1014C - a novel cabazitaxel against drug resistant prostate cancer, SP1030C - novel bendamustine against chronic lymphocytic leukemia and non-Hodgkin’s lymphoma and SP1049C - a novel injectable anthracycline platform drug against chemoresistant cancers. The company was founded by Valery Alakhov in 1994 and is headquartered in Pointe-Claire, Canada. | Health Technology |
Neurodyn, Inc.
 Neurodyn, Inc. Pharmaceuticals: MajorHealth Technology Neurodyn, Inc. provides neurological diseases detection. It discovers and develops bioactive compounds into treatments for neurological diseases. The company was founded by Christopher A. Shaw in 2013 and is headquartered in Charlottetown, PA. | Health Technology |
Fe Pharmaceuticals (Canada), Inc.
Fe Pharmaceuticals (Canada), Inc. Pharmaceuticals: MajorHealth Technology Fe Pharmaceuticals (Canada), Inc. operates as a research institution. It offers indication & treatment challenge, technical innovation and market services. The company was founded by William M. Cheliak and Bruce Holbein and is headquartered in Halifax, Canada. | Health Technology |
Panag Pharma, Inc.
Panag Pharma, Inc. Pharmaceuticals: MajorHealth Technology Panag Pharma, Inc. engages in the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Its product Topical A, provides a new approach to the treatment of chronic pain and inflammation. The company was founded by Mary Lynch, Melanie Kelly, Christian Lehmann, and Orlando Hung and is headquartered in Halifax, Canada. | Health Technology |
| MedBiome, Inc. |